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Abstract
Tuberculous meningitis (TBM) is the most lethal and disablingBackground: 
form of tuberculosis. Delayed diagnosis and treatment, which is a risk factor for
poor outcome, is caused in part by lack of availability of diagnostic tests that
are both rapid and accurate. Several attempts have been made to develop
clinical scoring systems to fill this gap, but none have performed sufficiently well
to be broadly implemented. We aim to identify and validate a set of clinical
predictors that accurately classify TBM using individual patient data (IPD) from
published studies.
We will perform a systematic review and obtain IPD from studiesMethods: 
published from the year 1990 which undertook diagnostic testing for TBM in
adolescents or adults using at least one of, microscopy for acid-fast bacilli,
commercial nucleic acid amplification test for   orMycobacterium tuberculosis
mycobacterial culture of cerebrospinal fluid.  Clinical data that have previously
been shown to be associated with TBM, and can inform the final diagnosis, will
be requested. The data-set will be divided into training and test/validation
data-sets for model building. A predictive logistic model will be built using a
training set with patients with definite TBM and no TBM. Should it be warranted,
factor analysis may be employed, depending on evidence for multicollinearity
or the case for including latent variables in the model.
We will systematically identify and extract key clinical parametersDiscussion: 
associated with TBM from published studies and use a ‘big data’ approach to
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 associated with TBM from published studies and use a ‘big data’ approach to
develop and validate a clinical prediction model with enhanced generalisability.
The final model will be made available through a smartphone application.
Further work will be external validation of the model and test of efficacy in a
randomised controlled trial.
Keywords
Tuberculous meningitis, multivariable prediction rule, machine learning,
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Introduction
Tuberculosis remains a major global health problem, with the 
most lethal and disabling form being tuberculous meningitis 
(TBM), of which there are more than 100,000 new cases each 
year1. Mortality is high, particularly in children and patients who 
are co-infected with HIV-12. The diagnosis is often delayed by 
the insensitive and lengthy culture technique required for disease 
confirmation, with delayed diagnosis and treatment being 
important risk factors for poor outcome1. Recently introduced 
nucleic acid amplification tests (NAATs) allow more rapid detec-
tion of TBM. Pooled specificity of 98.0% and 90% for Xpert 
MTB/RIF and Xpert MTB/RIF Ultra respectively, suggest that they 
are effective rule-in tests with the potential to speed up diagnosis 
and reduce unnecessary treatments for alternative conditions in 
some patients. However, the pooled sensitivity is 71.1% and 90% 
respectively, which is even lower for patients with HIV (58% to 
81%)3. Given the extremely high mortality if treatment is withheld 
from patients with TBM, these values are unlikely to be sufficient 
evidence to withhold treatment when negative in most patients. 
Improved strategies to rapidly and accurately diagnose TBM 
are urgently needed1.
A major stumbling block in TBM research had been the absence 
of a single reference standard test or standardised diagnostic 
criteria. In 2010, a committee of 41 international experts in the 
field developed consensus case definitions for TBM for use in 
clinical research4. These case definitions have helped to stand-
ardise research but are not appropriate for use in routine clinical 
care as they depend on variables such as cerebrospinal fluid 
(CSF) culture results, which can take up to 6 weeks to become 
positive and may include brain imaging, which is not available in 
many resource constrained settings. 
Another approach to improving rapid diagnosis in TBM, 
particularly in resource-limited settings where the majority of 
cases occur, is to develop and validate multivariable prediction 
models. At least 10 models have been published for the diagno-
sis of TBM, but a major limitation is that their performance is 
variable in different populations and settings1. A major reason 
for heterogeneous model performance across different settings 
and populations is case mix variation, which refers to the 
distribution of important predictor variables such as HIV status 
and age, and the prevalence of TBM. Case mix variation across 
different settings or populations can lead to genuine differ-
ences in the performance of a prediction model, even when the 
true predictor effects are consistent (that is, when the effect of a 
particular predictor on outcome risk is the same regardless of 
the study population)5. 
Recent studies have shown how big datasets can be used to exam-
ine heterogeneity and improve the predictive performance of a 
model across different populations, settings, and subgroups6–8. 
Individual patient data meta-analysis is preferred to aggregate 
data meta-analysis, as risk scores can be generated and validated, 
and multiple individual level factors can be examined in 
combination9. 
Objectives
1.    Conduct a systematic review to identify studies that applied 
systematic diagnostic strategies for TBM in adolescents 
and adults presenting with meningitis
2.    Establish an international collaboration among TBM 
research groups who are willing to provide individual 
patient data (IPD)
3.    Use IPD to develop a clinical prediction model that 
estimates the probability of TBM in adolescent and 
adults, based on clinical and laboratory data that is 
routinely available within 48 hours of initial evaluation
Secondary objectives include an assessment of the number 
and quality of studies addressing the diagnosis of TBM, as well 
as an analysis of demographic and clinical characteristics of 
cases and non-cases of TBM.
Protocol
A systematic review and IPD meta-analysis will be performed 
according to Preferred Reporting Items for Systematic review 
and Meta-Analysis of IPD (PRISMA-IPD) guidelines10.
Identification of studies
Potentially eligible studies will be identified by an extensive 
search of electronic databases, manual search of reference lists and 
by contacting researchers with interest and expertise in meningitis 
who may have access to unpublished studies.
We have designed a broad search strategy to maximise sensi-
tivity. We will combine medical subject heading (MeSH) and 
free text terms to identify relevant studies, see Table 1. We 
will search Medline (accessed via PubMed), Africa-Wide Infor-
mation and CINAHL (both accessed via EBSCO Host). We will 
not limit our searches by geographical location. The search 
will be restricted to studies published after 01 January 1990 and 
in English. The detailed search strategies will be presented in an 
online supplementary appendix. Reference lists of the selected 
articles and reviews will be searched manually to identify 
additional relevant studies.
Types of studies
Inclusion criteria
•    Randomized controlled trials, cross-sectional studies, and 
observational cohort studies
•    Participants presenting to care with clinical meningitis
•    Use of at least 1 of microscopy for acid-fast bacilli, 
commercial nucleic acid amplification test (NAAT) for 
Mycobacterium tuberculosis or mycobacterial culture of 
CSF to diagnose TBM
•    Study includes a minimum of 10 participants aged ≥ 13 
years
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Exclusion criteria
•    Case-control studies and case reports/series of patients 
with confirmed TBM
•    Participants taking anti-TB drugs at the time of their 
evaluation
•   Non-English articles
•   Studies published before 1990
•   Full text unable to be located
•   Studies not in humans
Screening and study selection
Duplicate studies will be removed. Study selection will follow 
the process described in the Cochrane Handbook of Systematic 
Reviews and PRISMA-IPD statements10. Two investigators will 
independently screen titles and abstracts to remove irrelevant 
studies. Full text review will be performed on the remaining 
studies to determine eligibility. Any disagreements will be 
resolved by consensus or in consultation with a third reviewer.
Data extraction
Data will be extracted on a proforma, independently by two 
review authors on study level variables: study setting and dates; 
contact details; inclusion criteria and exclusion criteria, and 
number of patients. Corresponding authors of studies identified 
as eligible after full text review will be contacted with a request 
to provide anonymised individual patient data. IPD for vari-
ables that have previously been shown to be predictive of 
TBM1 and competing diagnoses will be requested, Table 2. 
Investigators will be requested to share their anonymised data 
after obtaining a signed agreement.
Data management
Investigators will be asked to share anonymised individual 
patient data, preferably electronically using encrypted files and 
other secure data transfer technologies using standardised data 
collection forms. Only study collaborators will have access to 
the combined IPD data available in Box. Box Secure Storage is 
a cloud storage and collaboration service configured to meet 
the security standards for HIPAA data. Data will remain stored 
in Box for the duration of the study and will not be used or 
sold for any commercial purpose.
Authorship
Authors providing IPD will be asked to nominate co-authors 
to expand the expertise of the review group, including review of 
preliminary findings and manuscript authorship. The number of 
co-authors will depend on the amount of data supplied, 1 author 
for <100 patients, 2 authors for >100 and <250 patients, and 3 
authors for >250 patients.
Quality assessment
Quality assessment in terms of risk of bias and applicability for 
each included study will be performed according the QUADAS-2 
tool for diagnostic accuracy studies11. This tool comprises 4 
domains: patient selection, index test, reference standard, and 
flow and timing. Each domain is assessed in terms of risk of 
bias, and the first 3 domains are also assessed in terms of 
Table 1. Proposed search terms.
Search Query
#1 Search tuberculosis meningitis Field: Title/Abstract
#2 Search “tuberculosis, meningeal”[MeSH ]
#3 Search cerebral tuberculosis Field: Title/Abstract
#4 Search “brain tuberculosis” Field: Title/Abstract
#5 Search TBM Field: Title/Abstract
#6 Search ((((tuberculosis meningitis) OR “tuberculosis, meningeal”[MeSH Terms]) OR 
“cerebral tuberculosis“) OR “brain tuberculosis”) OR TBM
#7 Search “Diagnosis”[Majr]
#8 Search diagnosis or diagnostic Field: Title/Abstract
#9 Search “clinical scores” or “clinical scoring” Field: Title/Abstract
#10 Search “Research Design”[Mesh]
#11 Search predictor* or predictive Filters: Field: Title/Abstract
#12 Search “clinical predict*” Field: Title/Abstract
#13 Search “clinical feature*” Field: Title/Abstract
#14 Search (((#13 OR ((#12) OR ((#11) OR ((#10) OR ((#9) OR #8 OR #7 Filters: Humans
#15 Search #14 AND #6 Filters: Humans
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concerns regarding applicability. Signalling questions are included 
to help judge risk of bias.
Data synthesis
1.    Review and descriptive analysis of available parameters 
and data completeness for contributing datasets.
The contributing datasets will be reviewed for sample size, 
available parameters and data completeness, to inform the selec-
tion of a modelling approach. A descriptive analysis will be 
undertaken to understand similarities and differences between 
the contributing datasets. Participant characteristics, clinical 
features, and test results will be summarized for each contrib-
uting dataset and compared across datasets using chi-square, 
t-tests, or non-parametric methods as warranted. Additionally, 
participant characteristics and clinical features will be further 
evaluated for heterogeneity via IPD meta-analysis accounting for 
random effects.
2. Developing a Predictive model
Participants will be categorised as definite TBM if they have one 
of the following-
•    At least one of acid-fast bacilli seen in the CSF; 
Mycobacterium tuberculosis cultured from the CSF; or a 
CSF positive commercial NAAT
•    Acid-fast bacilli seen in the context of histological 
changes consistent with tuberculosis in the brain or spinal 
cord at autopsy
•    Culture positive extra-neural TB and no other definitive 
cause for clinical meningitis
Participants will be categorised as definitely not TBM if they-
•    Do not fulfil the criteria for definite TBM and either an 
alternative diagnosis is made or they fully recovered, 
without antituberculosis chemotherapy, 3 months after 
admission
Participants will be categorised as possible TBM if they-
•    Do not meet the criteria for either definite TBM or 
definitely not TBM
Model development will initially be carried out using partici-
pants with either definite TBM or definitely not TBM. The model 
will then be applied to participants with possible TBM. First, a 
training dataset will be generated using a proportion of partici-
pants from each contributing dataset that are selected at random 
for inclusion in the combined training dataset. This method 
ensures that there is representation of each contributing dataset 
in the development of the TBM diagnostic algorithm. Second, 
clustering in the data will be explored using a variety of methods 
including Gaussian Mixture Models and cluster analysis (latent 
Table 2. Individual patient data that will be requested from authors. LAM= lipoarabinomannan NAAT= nucleic acid amplification 
test.
Clinical data at presentation Laboratory results (blood) Laboratory results (CSF)
•   Age* 
•   Sex* 
•   Presence of extrapyramidal movements* 
•   Presence of neck stiffness* 
•   Duration of symptoms* 
•   Focal neurological deficit (including cranial nerve palsy)* 
•   Temperature* 
•   Glasgow Coma Scale* 
•   AVPU score*
•   HIV sero-status* 
•   Total leukocytes* 
•   CD4 count* 
•   Glucose*
•   Appearance* 
•   Total leukocytes* 
•   Total neutrophils* 
•   Total lymphocytes* 
•   Protein* 
•   Glucose* 
•   Gram stain* 
•   Adenosine deaminase activity* 
•   Bacterial culture 
•   India ink stain* 
•   Cryptococcal antigen* and culture 
•   Microscopy for acid-fast bacilli 
•   Mycobacterial culture 
•   NAAT for Mycobacterium tuberculosis 
•   NAAT for any virus 
•   Syphilis serology* 
•    Any other test informing an alternative 
diagnosis
Laboratory results (urine, sputum and serous effusions) Radiological investigations Autopsy
•   Urine LAM* 
•   Microscopy for acid-fast bacilli* 
•   Mycobacterial culture 
•   NAAT for Mycobacterium tuberculosis*
•   Chest X-ray* 
•    Abdominal ultrasound 
scan
•   CT brain 
•   MRI brain
•   Histological results from autopsy
*Factors chosena priori to be used to develop the initial model
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component analysis (LCA), Spectral Clustering, KMeans). 
This step serves as a tool to elucidate case-mix variation within 
TBM diagnostic categories (confirmed, probable, possible/ 
suspected, and not-TBM), which will inform TBM diagnostic 
prediction and TBM prediction model development. Finally, the 
model will be developed using inputs that have been chosen a 
priori as they are known to predict TBM, are routinely avail-
able to clinicians within 48 hours of admission and are not 
used part of the definition of definite and definitely not TBM 
(Table 2). The model will be developed using machine learning 
techniques including logistic regression, classification and 
regression analysis, and random forest classifier analysis. The 
training set will be calibrated to optimize the model coefficients 
for best predictive accuracy using AUC-ROC score. 
3. Testing the model for internal validity
Using the testing/validation dataset, we will calculate overall 
sensitivity, specificity, positive predictive value, and negative 
predictive to assess the accuracy of the algorithm in predicting 
TBM. The model will also be validated using ‘internal-external 
cross-validation’, which is a multiple validation approach that 
accounts for multiple studies by rotating which are used toward 
model development and validation7. Each contributing study 
will be excluded from the available set, and the remainder 
will be used to develop the diagnostic model; the excluded 
study will then be used to validate the model externally. This 
process will be repeated with each study being omitted in 
turn, allowing the consistency of the developed model and its 
performance to be examined on multiple occasions.
4. Sensitivity analysis
We will perform sensitivity analyses to explore the contributions 
of risk of bias on the final model(s) by limiting inclusion in the 
meta-analysis to the following.
•    Studies that used consecutive or random selection of 
participants based on a clinical presentation consistent 
with TBM
•    Studies that investigated all patients for TBM regardless 
of other CSF findings
•    Studies using CSF mycobacterial culture as the reference 
standard
Registration
This review is registered with PROSPERO, number 
CRD42018110501.
Presenting and reporting of results
We will report the results according to the Preferred Reporting 
Items for a Systematic Review and Meta-analysis of Indi-
vidual Participant Data Statement (PRISMA-IPD)10. This will 
include a flow diagram to summarise the study selection process 
and detail the reasons for exclusion of studies screened as 
full text. We will publish our search strategy and quality-scoring 
tool as supplementary documents. Quantitative data will be 
presented in evidence tables of individual studies as well as in 
summary tables. We plan to report on quality scores and risk of 
bias for each eligible study. This may be tabulated and accom-
panied by narrative summaries. A descriptive analysis of the 
strength of evidence assessment will be reported. The final 
prediction model(s), that is, the variable-selected model(s) with 
the highest area under the receiver operating characteristic 
curve (AUC), will be implemented in a Smart phone application 
and a Web-based calculator and graphically depicted using 
nomograms.
Discussion
TBM is a serious public health concern with delayed diagnosis 
and treatment being important risk factors for poor outcome1. 
At least 10 attempts have been made to develop clinical predic-
tion models to aid the rapid diagnosis of TBM but none have 
been broadly successful. The aim of this project is to combine 
data from multiple sources to develop and internally validate 
a novel clinical prediction model, which will be made easily 
available as a smart phone application and a Web-based calculator. 
By combining data from multiple geographical locations and 
using advanced machine learning techniques it is hoped that 
we can develop a model that is broadly generalizable around 
the world. Further work will involve external validation of the 
model(s) and testing in randomised controlled trials.
Ethics
No specific ethical approval has been sought for this system-
atic review. Authors who submit IPD will be asked to confirm 
that the dissemination of anonymised data was included in the 
original patient consent document.
Data availability
Underlying data
No data is associated with this article.
Reporting guidelines
Figshare: PRISMA-P checklist for The diagnosis of tuberculous 
meningitis in adults and adolescents: protocol for a systematic 
review and individual patient data meta-analysis to inform a 
multivariable prediction model, https://doi.org/10.6084/
m9.figshare.7628639.v112
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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